1. Home
  2. MVO vs MRKR Comparison

MVO vs MRKR Comparison

Compare MVO & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MVO

MV Oil Trust Units of Beneficial Interests

HOLD

Current Price

$2.85

Market Cap

26.3M

Sector

Energy

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.56

Market Cap

23.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVO
MRKR
Founded
2006
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.3M
23.0M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
MVO
MRKR
Price
$2.85
$1.56
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
326.5K
152.9K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
17.46%
N/A
EPS Growth
N/A
33.61
EPS
1.46
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$644.02
P/E Ratio
$2.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.97
$0.81
52 Week High
$6.40
$4.07

Technical Indicators

Market Signals
Indicator
MVO
MRKR
Relative Strength Index (RSI) 60.27 54.95
Support Level $1.11 $1.33
Resistance Level $3.37 $1.69
Average True Range (ATR) 0.28 0.13
MACD 0.06 0.04
Stochastic Oscillator 63.63 60.00

Price Performance

Historical Comparison
MVO
MRKR

About MVO MV Oil Trust Units of Beneficial Interests

MV Oil Trust is a statutory trust. The trust was created to acquire and hold the net profits interest for the benefit of the Trust unitholders.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: